GSK enters agreement to acquire RAPT Therapeutics
Jan 20, 2026 · GSK plc (LSE/NYSE: GSK) today announced that it has entered a definitive agreement to acquire RAPT Therapeutics (“RAPT”) (NASDAQ: RAPT), a California-based, clinical-stage …
Investor Relations | RAPT Therapeutics, Inc.
Jan 7, 2026 · The Investor Relations website contains information about RAPT Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Press Releases | RAPT Therapeutics, Inc.
The Investor Relations website contains information about RAPT Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
RAPT Therapeutics Announces FDA Clearance of IND Application to …
Sep 29, 2025 · About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel …
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s ...
Jan 6, 2025 · About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients …
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial ...
Nov 27, 2023 · About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small …
Stock Information - RAPT Therapeutics, Inc.
The Investor Relations website contains information about RAPT Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc.
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon ...
Nov 11, 2024 · About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small …
RAPT Therapeutics Names Two Industry Veterans to its Board of …
Jun 23, 2025 · About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel …